# DESCRIPTION

## FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

- acknowledge government support

## BACKGROUND

- motivate nSMase2 inhibitors

## SUMMARY

- outline DPTIP methods and uses

## DETAILED DESCRIPTION

- provide context for embodiments

### I. Discovery of 2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase-2) for the Treatment of Neurodegenerative and Oncologic Diseases

- introduce DPTIP as nSMase2 inhibitor
- describe screening process for DPTIP
- compare DPTIP to existing inhibitor GW4869
- discuss potential therapeutic applications of DPTIP
- provide examples of neurodegenerative diseases treatable with DPTIP
- provide examples of oncologic diseases treatable with DPTIP
- describe method for treating neurodegenerative diseases with DPTIP
- describe method for treating cancer with DPTIP
- describe method for treating cardiac disease with DPTIP
- provide definitions for terms used in the disclosure
- introduce DPTIP as nSMase-2 inhibitor
- describe synergistic effect of DPTIP with other therapeutic agents
- define synergy index and pharmaceutical compositions
- discuss administration routes and dosage forms
- describe formulation techniques and pharmaceutically acceptable carriers
- outline effective dosages and pharmaceutical preparations
- provide definitions and clarifications for patent language

## EXAMPLES

- provide guidance

### Example 1

- introduce high throughput screening campaign
- motivate nSMase2 inhibitor development
- summarize background of nSMase2 in neurodegenerative diseases
- describe development of cell-free enzymatic assay
- outline HTS campaign and data analysis
- identify DPTIP as potent nSMase2 inhibitor
- characterize DPTIP's mode of inhibition and selectivity
- evaluate DPTIP's metabolic stability and pharmacokinetic profile
- demonstrate DPTIP's inhibition of exosome release in vitro and in vivo
- illustrate DPTIP's effects on brain inflammation biomarkers in vivo
- summarize DPTIP
- describe expression of human nSMase2
- outline fluorescence-based nSMase2 activity assay
- determine IC50 of selected compounds
- synthesize and characterize DPT
- evaluate metabolic stability
- analyze in vivo pharmacokinetics
- inhibit exosome release in vitro and in vivo

